Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company’s integrated epigenetics platform enables it to validate targets and generate small molecules impacting these targets to selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. The Company utilizes its platform to discover and design its wholly owned product candidates - CPI-0610 and CPI-0209. CPI -0610 inhibits BET proteins and CPI-0209 inhibits the EZH2 protein. The Company also continues to leverage its platform and its clinical experience to discover and develop additional product candidates.